Our team is comprised of scientists and industry leaders who are not only experts at their craft, but are creatives who think outside the box. Together with our world-class scientific advisors, we are both driven and well-positioned to overcome the hurdles ahead of us to bring impactful new therapies to patients in need.
The Remix Team
Peter Smith, PhD
Co-Founder, Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Pete received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Zaven Kaprielian, PHD
Chief Scientific Officer
Zaven is Chief Scientific Officer of Remix Therapeutics. He brings extensive research and drug discovery experience, as well as deep domain expertise in Neuroscience to the team. Most recently, he was a venture partner at the Dementia Discovery Fund managed by SV Health Investors, where he focused on company creation. Prior to that he was a director of neuroscience research at Amgen in Cambridge, MA, and managed teams tasked with developing new therapeutics for neurodegenerative disorders and chronic pain. Before joining industry, he was a faculty member at the Albert Einstein College of Medicine directing a research group investigating the molecular mechanisms underlying axon guidance and dendrite branching in the developing spinal cord and brain. Zaven received his PhD from The Johns Hopkins University and carried out postdoctoral training at the California Institute of Technology. He is excited about Remix’s unique approach of manipulating RNA processing for therapeutic benefit in a variety of indications.
Heather Wasserman, PhD
Chief Operating Officer, Chief Business Officer
Heather is responsible for corporate business development and operations at Remix. She joins after 7 years at Eli Lilly, where she gained extensive business knowledge while heading up immunology search and evaluation, emerging technologies and innovations and most recently global corporate business development during her tenure there. Heather received a PhD from the University of Georgia, and went on to complete a postdoctoral fellowship at Emory University. Heather is excited to work alongside Remix’s talented team focused on novel small molecule modulation of RNA processing.
Jesse Smith, PhD
Senior Vice President, Biology and Translational Sciences
Jesse works to define strategies for progression of Remix pipeline programs while vetting new target opportunities. Jesse has held numerous leadership positions in the biotech and pharmaceutical spaces. As VP of Biology at Epizyme Pharmaceuticals, his team advanced to the clinic the first EZH2 inhibitor, which was recently approved in two oncology indications. He received his PhD in Molecular Cancer Biology from Duke University Medical Center and was a postdoctoral fellow at the National Cancer Institute.
Dominic Reynolds, PhD
Senior Vice President, Chemistry
As head of chemistry, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds to reprogram RNA processing and forge a path to the clinic. Dominic has extensive experience in the biotech space and building successful biotech companies. Recent positions include drug discovery consultancy to two seed-stage companies at Third Rock Ventures and VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to that Dominic worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his PhD in synthetic chemistry from the University of Cambridge and conducted postdoctoral training at Harvard University where he focused on natural product synthesis.
Mike Seiler, PhD
Sr. Director, Bioinformatics and Data Science
Heading up computational biology, Michael brings a passion for RNA biology and processing to the Remix team. He joins with notable computational biology experience in the biotech space, most recently serving as head of computational biology at Arrakis Therapeutics and prior to that as a computational scientist leading splicing bioinformatics efforts at H3 Biomedicine. Michael completed his PhD in computational biology and molecular biophysics at Rutgers University and is excited to utilize his experience in further building a platform to harness powerful RNA processing to impact patients’ lives.
Fred Vaillancourt, PhD
Vice President, Biomolecular Sciences and Lead Discovery
Fred oversees the biomolecular sciences, screening and lead discovery effort at Remix Therapeutics. He joins the team with more than 15 years of experience in a range of roles in drug discovery, most recently serving as a consultant for Third Rock Ventures. Prior to that, Fred held various leadership roles at H3 Biomedicine and Boehringer Ingelheim. Now, Fred is motivated to push the current boundaries of drug discovery with the Remix team. He received his PhD in biochemistry and molecular biology from the University of British Columbia and completed his postdoctoral training as a Merck-sponsored Helen Hay Whitney Foundation fellow at Harvard Medical School.
Board Of Directors
Scott Biller, PhD
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Kevin Bitterman, PhD
Partner, Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Leon Chen, PhD
Partner, The Column Group
Leon is currently a Partner at The Column Group, a healthcare venture capital firm. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early stage biotech companies. In this capacity he took on interim management roles at E-Scape Bio, TranscripTx, and Adicet. He also served on the board of directors of Pionyr Immunotherapeutics and Logic Bio. Prior to that Leon was a Partner at Skyline Ventures and an entrepreneur in residence at Venrock. Leon started his career in 2002 as a founder of KAI Pharmaceuticals, which was acquired by Amgen in 2012 and led to the approval of Parsabiv in the US, Europe, and Japan. He holds a PhD in molecular pharmacology from Stanford School of Medicine, and an MBA from Stanford Graduate School of Business.
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.
Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020. Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Michael Rome, PhD
Managing Director, Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Peter Smith, PhD
Co-founder, Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team discovered and developed novel therapies with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Pete received his PhD from Cancer Research UK at Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Angela Brooks, PHD
University of California Santa Cruz
Christopher Burge, PHD
Massachusetts Institute of Technology
Benoit Chabot, PHD
University of Sherbrooke Canada
Ryan Corcoran, MD, PhD
MGH Cancer Center and Harvard Medical School
Will Fairbrother, PHD
Aaron Hoskins, PHD
University of Wisconsin
Juan Valcarcel, PHD
Center for Genomic Regulation, Barcelona
Rui Zhao, PHD
University of Colorado